Disc Medicine, INC 8-K filings

Disc Medicine's 2024 Annual Meeting saw the election of two Class I directors and the ratification of Ernst & Young LLP as the company's independent auditor.

Disc Medicine has announced a $178 million underwritten offering of common stock to fund research, clinical development, and general corporate purposes.

Disc Medicine presented updated clinical data for bitopertin in EPP, DISC-0974 in MF anemia, and initial data for DISC-3405 in healthy volunteers at the European Hematology Association 2024 Congress.

Disc Medicine reported its Q1 2024 financial results and provided updates on its clinical programs, including positive topline data from the AURORA trial for bitopertin.

Disc Medicine's Phase 2 AURORA study of bitopertin in EPP patients showed statistically significant reductions in protoporphyrin IX (PPIX) and improvements in phototoxic reactions and patient global impression of change.

Disc Medicine announced its 2023 financial results, highlighted by significant clinical advancements and a robust cash position, setting the stage for multiple data readouts in 2024.

Disc Medicine has appointed Pamela Stephenson as Chief Commercial Officer to lead the company's global commercialization strategy, as it advances into late-stage development.

Disc Medicine has appointed Jean Franchi as Chief Financial Officer and promoted Jonathan Yu to Chief Operating Officer, effective February 7, 2024.